CA2931518C - Viral vector manufacture - Google Patents

Viral vector manufacture Download PDF

Info

Publication number
CA2931518C
CA2931518C CA2931518A CA2931518A CA2931518C CA 2931518 C CA2931518 C CA 2931518C CA 2931518 A CA2931518 A CA 2931518A CA 2931518 A CA2931518 A CA 2931518A CA 2931518 C CA2931518 C CA 2931518C
Authority
CA
Canada
Prior art keywords
cell
virus
cells
cho
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2931518A
Other languages
English (en)
French (fr)
Other versions
CA2931518A1 (en
Inventor
Paul Michael Howley
Liang Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SEMENTIS Ltd
Original Assignee
SEMENTIS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013904242A external-priority patent/AU2013904242A0/en
Application filed by SEMENTIS Ltd filed Critical SEMENTIS Ltd
Publication of CA2931518A1 publication Critical patent/CA2931518A1/en
Application granted granted Critical
Publication of CA2931518C publication Critical patent/CA2931518C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151Methods of production or purification of viral material
    • C12N2710/24152Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2931518A 2013-11-01 2014-11-03 Viral vector manufacture Active CA2931518C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2013904242 2013-11-01
AU2013904242A AU2013904242A0 (en) 2013-11-01 Viral vector manufacture
AU2014900370A AU2014900370A0 (en) 2014-02-07 Orthopox vectors and propagation
AU2014900370 2014-02-07
PCT/AU2014/050330 WO2015061858A1 (en) 2013-11-01 2014-11-03 Viral vector manufacture

Publications (2)

Publication Number Publication Date
CA2931518A1 CA2931518A1 (en) 2015-05-07
CA2931518C true CA2931518C (en) 2021-03-09

Family

ID=53003022

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2931518A Active CA2931518C (en) 2013-11-01 2014-11-03 Viral vector manufacture

Country Status (24)

Country Link
US (2) US10544397B2 (enExample)
EP (2) EP3375882B1 (enExample)
JP (2) JP6682443B2 (enExample)
KR (1) KR102047030B1 (enExample)
CN (1) CN106255758B (enExample)
AU (1) AU2014344738B2 (enExample)
CA (1) CA2931518C (enExample)
CY (1) CY1121414T1 (enExample)
DK (2) DK3063278T3 (enExample)
ES (1) ES2670034T3 (enExample)
HR (1) HRP20180789T1 (enExample)
HU (1) HUE037718T2 (enExample)
LT (1) LT3063278T (enExample)
NO (1) NO3063278T3 (enExample)
NZ (1) NZ720241A (enExample)
PL (1) PL3063278T3 (enExample)
PT (1) PT3063278T (enExample)
RS (1) RS57290B1 (enExample)
RU (1) RU2658487C2 (enExample)
SG (1) SG11201603919XA (enExample)
SI (1) SI3063278T1 (enExample)
SM (1) SMT201800267T1 (enExample)
TR (1) TR201807128T4 (enExample)
WO (1) WO2015061858A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI728173B (zh) * 2016-08-19 2021-05-21 澳大利亞商賽門堤斯有限公司 病毒疫苗
JP2018081568A (ja) * 2016-11-17 2018-05-24 グローリー株式会社 紙幣収納装置および紙幣処理機
CA3258751A1 (en) * 2022-06-30 2024-01-04 Bavarian Nordic As Mammalian cell line for the production of modified Ankara vaccine virus (MVA)
EP4590841A2 (en) * 2022-09-20 2025-07-30 Aldevron, LLC Best1 vectors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2604183B1 (fr) * 1986-09-23 1988-12-30 Transgene Sa Sequence d'adn, vecteurs, virus recombinants et procede mettant en oeuvre des virus de la vaccine recombinants capables de se multiplier dans les cellules cho
EP0758397B1 (en) * 1994-04-29 2005-06-22 Baxter Healthcare S.A. Recombinant poxviruses with foreign polynucleotides in essential regions
DE60336653D1 (de) * 2002-08-07 2011-05-19 Bavarian Nordic As Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren
FR2884255B1 (fr) * 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
AU2007280004A1 (en) * 2006-08-04 2008-02-07 Dublin City University A method of producing recombinant biological products

Also Published As

Publication number Publication date
SG11201603919XA (en) 2016-07-28
CY1121414T1 (el) 2020-05-29
CN106255758B (zh) 2020-06-23
JP2016534755A (ja) 2016-11-10
RU2658487C2 (ru) 2018-06-21
TR201807128T4 (tr) 2018-06-21
EP3063278A4 (en) 2017-04-12
CA2931518A1 (en) 2015-05-07
HUE037718T2 (hu) 2018-09-28
CN106255758A (zh) 2016-12-21
AU2014344738B2 (en) 2019-03-21
WO2015061858A1 (en) 2015-05-07
EP3375882A1 (en) 2018-09-19
PT3063278T (pt) 2018-05-25
NZ720241A (en) 2019-10-25
EP3375882B1 (en) 2019-10-16
DK3375882T3 (da) 2019-12-16
US20200190482A1 (en) 2020-06-18
RS57290B1 (sr) 2018-08-31
EP3063278A1 (en) 2016-09-07
DK3063278T3 (en) 2018-06-06
SMT201800267T1 (it) 2018-07-17
US20170029784A1 (en) 2017-02-02
RU2016121425A (ru) 2017-12-04
EP3063278B1 (en) 2018-02-28
AU2014344738A1 (en) 2016-06-09
PL3063278T3 (pl) 2018-08-31
KR20160079868A (ko) 2016-07-06
JP2020039340A (ja) 2020-03-19
ES2670034T3 (es) 2018-05-29
KR102047030B1 (ko) 2019-11-20
HK1223395A1 (en) 2017-07-28
SI3063278T1 (sl) 2019-04-30
NO3063278T3 (enExample) 2018-07-28
LT3063278T (lt) 2018-07-10
US10544397B2 (en) 2020-01-28
HRP20180789T1 (hr) 2018-09-07
JP6682443B2 (ja) 2020-04-15

Similar Documents

Publication Publication Date Title
AU2019377141B2 (en) Enhanced systems for cell-mediated oncolytic viral therapy
US20200190482A1 (en) Viral vector manufacture
EP2488649A1 (en) Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
US20210113684A1 (en) Vector-based attenuated poxvirus vaccines
CN105039268A (zh) 表达鸭坦布苏病毒e蛋白的重组鸭瘟病毒及其构建方法和应用
CN116479016B (zh) 牛副流感病毒3型全长感染性克隆及其构建方法、用途
HK1260426B (en) Viral vector manufacture
HK1260426A1 (en) Viral vector manufacture
CN118240879A (zh) 骨架质粒、重组质粒以及猴痘病毒颗粒和应用
HK1223395B (en) Viral vector manufacture
WO2023066920A1 (en) Recombinant african swine fever virus and uses thereof
CN102417907B (zh) 靶向抑制羊痘病毒ORF095基因的siRNA序列
CN102851293B (zh) 靶向抑制羊痘病毒ORF095基因的序列siRNA-165
Busha A Novel Selection Technology for the Discovery of High-Affinity Human Proteins
CN111206022A (zh) 一种表达拉沙热病毒空衣壳的重组病毒及其制备方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180423